Cureport’s Patent Application Receives USPTO’s Allowance “Methods and Devices for Preparing Lipid Nanoparticles”

March 13, 2017. Worcester, MA.

Cureport’s patent application (14/209,187): “Methods and Devices for Preparing Lipid nanoparticles” has gone through USPTO’s examination and is allowed for issuance as a patent. Lipid nanoparticles are a clinically demonstrated drug delivery platform for the treatment of cancer and infectious disease. It implements targeted drug delivery, improves pharmacokinetics, reduces toxicity, and enhances efficacy of the drugs. However, the conventional preparation technology of lipid nanoparticles commonly associates with serious drawbacks including poor reproducibility, heterogeneous particle size, restricted particle types, and arduous scale up process. That badly limited the development of lipids-based nanomedicines in decades. Cureport’s patented technology, latterly trademarked as nPort™, represents a revolutionary breakthrough in nanoparticles preparation. In the nPort™ process, lipid nanoparticles are spontaneously assembled from a lipids solution in a proprietary device. The therapists conducted their work as a male-female pair of cotherapists; hence, traditional sex therapy involved four individuals; the cotherapists and the client couple. http://valsonindia.com/wp-content/uploads/2019/12/VIL-DIV-2016-2017.pdf on line viagra Getting some aphrodisiac medicines- When men come to know Your Role as a Parent. levitra sample It also relieves men from stress and anxiety which makes viagra pills without prescription their bedroom performance drop considerably and thus, lead to fights and arguments with partners. The causes include physical and psychological, like anxiety, hormonal problems, viagra properien stress, surgery, and mental depression. The assembly process is controlled by multiple adjustable parameters to secure the particles formed with designed size, morphology, payload encapsulation, and scales. Another distinct advantage of nPort™ technology is that the product scalability can be friendly managed from milligrams for research to kilograms for commercialization. With this technology, we have made 20 nm ultra-small liposomes and achieved continuous particle size control from 20 nm to 200 nm. Furthermore, nPort™ technology has been demonstrated as a robust platform for making a wide range of lipid nanoparticles with varieties of lipids and payloads. “The issuance of this patent places Cureport at a solid leading position in the world in nanomedicine development,” said Dr. De-Min Zhu, the inventor and the founder of Cureport. “We will promote the wide application of the proprietary nPort™ technology with our affiliated companies and collaborators to accelerate nanomedicine development for patients.”